ORMP
insider transactionsORAMED PHARMACEUTICALS INC. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
No open-market buys or sells this period. The trades below are grants, option exercises and gifts, which carry no market price.
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Other·F
Chief Scientific Officer
$1.4M
435.1K sh · $3.31
Own -28%
-
Other·F
Nadav Kidron KEY
President and CEO
$148.3K
44.8K sh · $3.31
Own -1%
-
Grant·A
Director
$0
7.7K sh
Own New
-
Grant·A
Director
$0
7.7K sh
Own New
-
Grant·A
Chief Scientific Officer
$0
119.6K sh
Own +8%
-
Grant·A
Nadav Kidron KEY
President and CEO
$0
167.0K sh
Own +5%
-
Grant·A
COO & CBO
$0
95.9K sh
Own +9%
-
Grant·A
Avraham Gabay KEY
Chief Financial Officer
$0
95.9K sh
Own +15%
-
Other·G
Nadav Kidron KEY
President and CEO
$0
100.0K sh
Own -3%
-
Exercise·M
Chief Scientific Officer
$0
19.0K sh
Own New
-
Exercise·M
Chief Scientific Officer
$0
19.0K sh
Own +1%
-
Exercise·M
Nadav Kidron KEY
President and CEO
$0
109.0K sh
Own New
-
Exercise·M
Nadav Kidron KEY
President and CEO
$0
109.0K sh
Own +3%
-
Exercise·M
COO & CBO
$0
19.0K sh
Own New
-
Exercise·M
COO & CBO
$0
19.0K sh
Own +2%
-
Exercise·M
Avraham Gabay KEY
Chief Financial Officer
$0
19.0K sh
Own New
-
Exercise·M
Avraham Gabay KEY
Chief Financial Officer
$0
19.0K sh
Own +3%
-
Other·G
Chief Scientific Officer
$0
86.2K sh
Own -6%
-
Grant·A
Avraham Gabay KEY
Chief Financial Officer
$0
19.0K sh
Own New
-
Grant·A
Avraham Gabay KEY
Chief Financial Officer
$0
115.0K sh
Own +22%
-
Grant·A
Avraham Gabay KEY
Chief Financial Officer
$0
81.2K sh
Own +19%
-
Grant·A
Director
—
6.2K sh
Own +6%
-
Grant·A
Director
—
30.0K sh
Own +39%
-
Grant·A
Director
—
6.2K sh
Own +6%
-
Grant·A
Director
—
30.0K sh
Own +44%
-
Grant·A
Director
—
3.5K sh
Own +3%
-
Grant·A
Director
—
30.0K sh
Own +33%
-
Grant·A
Director
—
4.9K sh
Own +3%
-
Grant·A
Director
—
30.0K sh
Own +23%
-
Grant·A
Chief Scientific Officer
$0
19.0K sh
Own New
-
Grant·A
Chief Scientific Officer
$0
115.0K sh
Own +9%
-
Grant·A
Chief Scientific Officer
$0
121.3K sh
Own +10%
-
Grant·A
Nadav Kidron KEY
President and CEO
$0
109.0K sh
Own New
-
Grant·A
Nadav Kidron KEY
President and CEO
$0
327.0K sh
Own +11%
-
Grant·A
Nadav Kidron KEY
President and CEO
$0
232.6K sh
Own +9%
-
Grant·A
COO & CBO
$0
19.0K sh
Own New
-
Grant·A
COO & CBO
$0
115.0K sh
Own +12%
-
Grant·A
COO & CBO
$0
97.3K sh
Own +12%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Mar 30, 2026 | Miriam Kidron | Other F | 435.1K | $1.4M |
| Mar 30, 2026 | Nadav Kidron KEY | Other F | 44.8K | $148.3K |
| Mar 25, 2026 | Miriam Kidron | Grant A | 7.7K | $0 |
| Mar 25, 2026 | Nadav Kidron | Grant A | 7.7K | $0 |
| Mar 17, 2026 | Miriam Kidron | Grant A | 119.6K | $0 |
| Mar 17, 2026 | Nadav Kidron KEY | Grant A | 167.0K | $0 |
| Mar 17, 2026 | Joshua Hexter | Grant A | 95.9K | $0 |
| Mar 17, 2026 | Avraham Gabay KEY | Grant A | 95.9K | $0 |
| Mar 12, 2026 | Nadav Kidron KEY | Other G | 100.0K | $0 |
| Jan 22, 2026 | Miriam Kidron | Exercise M | 19.0K | $0 |
| Jan 22, 2026 | Miriam Kidron | Exercise M | 19.0K | $0 |
| Jan 22, 2026 | Nadav Kidron KEY | Exercise M | 109.0K | $0 |
| Jan 22, 2026 | Nadav Kidron KEY | Exercise M | 109.0K | $0 |
| Jan 22, 2026 | Joshua Hexter | Exercise M | 19.0K | $0 |
| Jan 22, 2026 | Joshua Hexter | Exercise M | 19.0K | $0 |
| Jan 22, 2026 | Avraham Gabay KEY | Exercise M | 19.0K | $0 |
| Jan 22, 2026 | Avraham Gabay KEY | Exercise M | 19.0K | $0 |
| Jan 14, 2026 | Miriam Kidron | Other G | 86.2K | $0 |
| Dec 31, 2025 | Avraham Gabay KEY | Grant A | 19.0K | $0 |
| Dec 31, 2025 | Avraham Gabay KEY | Grant A | 115.0K | $0 |
| Dec 31, 2025 | Avraham Gabay KEY | Grant A | 81.2K | $0 |
| Dec 31, 2025 | Daniel Aghion | Grant A | 6.2K | — |
| Dec 31, 2025 | Daniel Aghion | Grant A | 30.0K | — |
| Dec 31, 2025 | Yehuda Reznick | Grant A | 6.2K | — |
| Dec 31, 2025 | Yehuda Reznick | Grant A | 30.0K | — |
| Dec 31, 2025 | Benjamin Shapiro | Grant A | 3.5K | — |
| Dec 31, 2025 | Benjamin Shapiro | Grant A | 30.0K | — |
| Dec 31, 2025 | Arie Mayer | Grant A | 4.9K | — |
| Dec 31, 2025 | Arie Mayer | Grant A | 30.0K | — |
| Dec 31, 2025 | Miriam Kidron | Grant A | 19.0K | $0 |
| Dec 31, 2025 | Miriam Kidron | Grant A | 115.0K | $0 |
| Dec 31, 2025 | Miriam Kidron | Grant A | 121.3K | $0 |
| Dec 31, 2025 | Nadav Kidron KEY | Grant A | 109.0K | $0 |
| Dec 31, 2025 | Nadav Kidron KEY | Grant A | 327.0K | $0 |
| Dec 31, 2025 | Nadav Kidron KEY | Grant A | 232.6K | $0 |
| Dec 31, 2025 | Joshua Hexter | Grant A | 19.0K | $0 |
| Dec 31, 2025 | Joshua Hexter | Grant A | 115.0K | $0 |
| Dec 31, 2025 | Joshua Hexter | Grant A | 97.3K | $0 |
About ORMP insider trading
This page tracks insider transactions for ORAMED PHARMACEUTICALS INC. (ORMP) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.